BioCryst seeks FDA OK for IV flu antiviral peramivir
This article was originally published in Scrip
Executive Summary
Shares of BioCryst Pharmaceuticals got a 4.9% boost on 20 December on word the company had finally submitted its new drug application (NDA) for peramivir to the FDA seeking approval of the its intravenous antiviral as a treatment for acute uncomplicated influenza in adults.